Sodium-glucose co-transporter-2 inhibitors in patients with type 2 diabetes mellitus without established cardiovascular disease: Do they have a role in primary prevention?
Open Access
- 28 January 2021
- journal article
- research article
- Published by Elsevier BV in Metabolism Open
- Vol. 10, 100082
- https://doi.org/10.1016/j.metop.2021.100082
Abstract
No abstract availableKeywords
This publication has 71 references indexed in Scilit:
- Sodium–glucose linked transporter-2 inhibitors: potential for renoprotection beyond blood glucose lowering?Kidney International, 2014
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet Diabetes & Endocrinology, 2013
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASDEuropean Heart Journal, 2013
- SGLT inhibitors in management of diabetesThe Lancet Diabetes & Endocrinology, 2013
- American Association of Clinical Endocrinologists' Comprehensive Diabetes Management Algorithm 2013 Consensus Statement - Executive SummaryEndocrine Practice, 2013
- Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exerciseDiabetes, Obesity and Metabolism, 2013
- Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studiesThe Lancet, 2010
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and ExerciseDiabetes Care, 2010
- Effect of a Multifactorial Intervention on Mortality in Type 2 DiabetesThe New England Journal of Medicine, 2008
- Application of cardiovascular disease risk prediction models and the relevance of novel biomarkers to risk stratification in Asian IndiansVascular Health and Risk Management, 2008